Refractory invasive aspergillosis controlled with posaconazole and pulmonary surgery in a patient with chronic granulomatous disease: Case report

Italian Journal of Pediatrics

Volumn 40, Issue 1, 2014, Pages

  Kepenekli, Eda ^a   Soysal, Ahmet ^a,b   Kuzdan, Canan ^a   Ermerak, Nezih Onur ^a   Yüksel, Mustafa ^a   Bakr, Mustafa ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Chronic granulomatous disease; Invasive pulmonary aspergillosis; Posaconazole

Indexed keywords

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FOLLOW-UP STUDIES; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; MALE; PNEUMONECTOMY; TOMOGRAPHY, X-RAY COMPUTED; TRIAZOLES;

EID: 84892177882     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-40-2     Document Type: Article

References (16)

1. Chronic granulomatous disease. Heyworth PG, Cross AR, Curnutte JT, Curr Opin Immunol 2003 15 578 584 10.1016/S0952-7915(03)00109-2 14499268 (Pubitemid 37130200)
2. Modern management of chronic granulomatous disease. Seger RA, Br J Haematol 2003 140 255 266
3. Genetic, biochemical and clinical features of chronic granulomatous disease. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM, Medicine 2000 79 170 200 10.1097/00005792-200005000-00004 10844936 (Pubitemid 30327531)
4. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Seger RA, Gungor T, Belohradsky BH, et al. Blood 2002 100 4344 4350 10.1182/blood-2002-02-0583 12393596 (Pubitemid 35429672)
5. Treatment of chronic granulomatous disease with myeloablative conditioning and t-cell depleted hematopoietic allograft. Horwitz ME, Barret AJ, Brown MR, et al. N Engl J Med 2001 344 881 888 10.1056/NEJM200103223441203 11259721 (Pubitemid 32224396)
6. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Martire B, Rondelli R, Soresina A, et al. Clin Immunol 2008 126 155 164 10.1016/j.clim.2007.09.008 18037347
7. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Blumental S, Mouy R, Mahlaoui N, Bougnoux ME, Debré M, Beauté J, Lortholary O, Blanche S, Fischer A, Clin Infect Dis 2011 53 12 159 e169 10.1093/cid/cir731 22080130
8. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. Mouy R, Veber F, Blanche S, et al. J Pediatr 1994 125 998 1003 10.1016/S0022-3476(05)82023-2 7996377 (Pubitemid 24379140)
9. Itraconazole to prevent fungal infections in chronic granulomatous disease. Gallin JI, Alling DW, Malech HL, et al. N Engl J Med 2003 348 2416 2422 10.1056/NEJMoa021931 12802027 (Pubitemid 36682820)
10. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Patterson TF, Kirkpatrick WR, White M, et al. Medicine 2000 79 250 260 10.1097/00005792-200007000-00006 10941354 (Pubitemid 30616973)
11. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Marr KA, Patterson T, Denning D, Infect Dis Clin North Am 2002 16 875 894 10.1016/S0891-5520(02)00035-1 12512185 (Pubitemid 35477517)
12. Invasive fungal infection in chronic granulomatous disease: insights into pathogenesis and management. Falcone EL, Holland SM, Curr Opin Infect Dis 2012 25 6 658 669 10.1097/QCO.0b013e328358b0a4 22964947
13. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease. Beaute J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux ME, Mouy R, et al. Pediatr Infect Dis J 2011 30 1 57 62 10.1097/INF.0b013e3181f13b23 20700078
14. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Clin Infect Dis 2008 46 327 360 10.1086/525258 18177225 (Pubitemid 351265310)
15. Treatment of invasive aspergillozis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Clin Infect Dis 2007 44 2 22 10.1086/508774 17143808 (Pubitemid 44968977)
16. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Segal BH, Barnhart LA, Anderson VL, Walsh TJ, Malech HL, Holland SM, Clin Infect Dis 2005 40 1684 1688 10.1086/430068 15889369 (Pubitemid 40720823)